Search for: "Mylan Pharmaceuticals v. FDA"
Results 181 - 200
of 233
Sort by Relevance
|
Sort by Date
28 Oct 2009, 6:15 am
(The SPC Blog) EU: European Federation of Pharmaceutical Industries and Associations unveils anti-counterfeit authentication system (IP Watch) US: Time Magazine on data exclusivity debate (Patent Docs) US: BIO's IPCC Conference: Behind the scenes look at patent cases - Mayo v Prometheus; Bilski v Doll; Laboratory Court of Am. [read post]
28 Oct 2009, 6:15 am
(The SPC Blog) EU: European Federation of Pharmaceutical Industries and Associations unveils anti-counterfeit authentication system (IP Watch) US: Time Magazine on data exclusivity debate (Patent Docs) US: BIO's IPCC Conference: Behind the scenes look at patent cases - Mayo v Prometheus; Bilski v Doll; Laboratory Court of Am. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz… [read post]
14 Oct 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb) Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no… [read post]
9 Sep 2009, 7:14 am
(America-Israel Patent Law) Avinza (Morphine) – US: King Pharmaceuticals, Elan files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs) Cipro (Ciprofloxacin) – US: California court rules that Bayer AG et al did not violate state antitrust law in Cipro reverse payment case (FDA Law Blog) Effexor (Venlafaxine) - Israel: Patent oppositions: should substance or procedural issues win out? [read post]
2 Sep 2009, 11:22 pm
Mylan Laboratories, Inc., 2008 WL 4813311, at *6-7 (D. [read post]
22 Jul 2009, 6:05 am
(PatLit) Levaquin (Levofloxacin) – US: CAFC awards only partial costs where depositions used in multiple cases from different district courts: Ortho-McNeil Pharmaceutical, Inc. v. [read post]
15 Jul 2009, 5:15 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: European Commission Competition DG releases final report on pharmaceutical sector (IPKat) (PatLit) (BLOG@IP::JUR) (IAM) (Managing Intellectual Property) (Intellectual Property Watch) (The SPC Blog) (IAM) US: Follow-on biologics proposals considered by US Senate HELP Committee; Committee passes amendment for 12-year biologics exclusivity period… [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs)… [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent… [read post]
10 Jun 2009, 9:02 pm
Seeking approval to market a generic version of levofloxacin, Defendants-Appellants Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc. filed an Abbreviated New Drug Application (ANDA) with the FDA. [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
20 May 2009, 5:18 am
’ (Patent Docs) Atripla/Truvada (Efavirenz, Emtricitabine, Tenofovir) – US: Gilead Sciences files second patent infringement lawsuit against Teva Pharmaceuticals over Emtricitabine, a component of Truvada and Atripla (SmartBrief) (The IP Factor) (GenericsWeb) Champix (Varenicline) – India: Pfizer responds to Dr Reddy’s post-grant opposition to Champix filed at Mumbai Patent Office (GenericsWeb) (Spicy IP) Corpril (Ramipril) – Hungary:… [read post]
23 Apr 2009, 10:00 pm
(Spicy IP) India: Assessing India’s innovation climate (Biotech Blog) Kenya’s anti-counterfeit legislation, India protest (Afro-IP) Mexico: Pharmaceutical trade marks: the Health Law pitfall for applicants (International Law Office) US: BIO IP Counsels’ Committee: Q Todd Dickinson and E Anthony Figg on patent reform (Patent Docs) US: Amgen VP makes case for longer exclusivity period in follow-on biologics legislation (Patent Docs) Products Cepham… [read post]
17 Apr 2009, 12:00 am
Ltd. sues 11 generics companies over Levaquin patents (Law 360) Lexapro (Escitalopram) – Netherlands District court invalidates Lundbeck’s patent EP ‘066 (IPKat) Lexapro (Escitalopram) - Baldwin’s rules explained (The SPC Blog) Lexapro (Escitalopram) – federal district Judge agrees to determine whether Forest Laboratories destroyed key documents (Law 360) Pegasys (PEG interferon alfa 2a) – Roche wins post grant opposition against Wockhardt… [read post]
9 Apr 2009, 7:52 am
(Part I - Patent Circle) (Part II – Patent Circle) Indian biogenerics on an upswing – US Promoting Innovation and Access to Life-Saving Medicine Act (Patent Baristas) US: Anti-reverse payment legislation Protecting Consumer Access to Generic Drugs Act of 2009 introduced in the House (Patent Docs) US: CAFC clarifies obviousness standard in context of cDNA cloning invention: In re Kubin (Holman's Biotech IP Blog) (Patent Docs) (Hal Wegner) (Philip Brooks' Patent… [read post]
27 Mar 2009, 8:00 am
; no skulduggery involved in pharma enquiry submission switch says EPO (IPKat) (IAM) India: Public sector IP and socially responsible licensing (Spicy IP) India: Pharma lobby wants a probe into delayed orders (Spicy IP) UK: Euro costs in UK litigation: Actavis UK Ltd v Novartis AG (PatLit) US: Two biosimilars bills introduced in the House: HR 1427, the Promoting Innovation and Access to Life Saving Medicine Act; and H.R. 1548, the Pathway to BioSimilars Act (California Biotech Law Blog)… [read post]
